Journal of Liquid Biopsy

The Journal of Liquid Biopsy is an open access journal published by Elsevier on behalf of the International Society of Liquid Biopsy, launched in 2023 and devoted to liquid biopsy biomarkers and their clinical implications, with a 2025 Journal Impact Factor of 5.0.《液体活检杂志》（The Journal of Liquid Biopsy）由（Elsevier）代表国际液体活检学会出版，2023 年创刊，为开放获取期刊，专注液体活检生物标志物及其临床意义，2025 年期刊影响因子为 5.0。

Scope

• The journal covers research into the molecular pathways analysed with liquid biopsy based biomarkers and their clinical implications.刊物涵盖以液体活检生物标志物分析的分子通路研究及其临床意义。
• Biomarkers of interest include circulating free DNA, circulating tumour DNA, microRNA, circulating tumour cells, extracellular vesicles and proteins.关注的标志物包括游离 DNA、循环肿瘤 DNA、微小 RNA、循环肿瘤细胞、细胞外囊泡与蛋白质。
• It encourages an integrated approach that combines molecular findings, technical aspects and clinical data.刊物鼓励结合分子发现、技术层面与临床数据的整合性研究。
• Papers that clarify the molecular mechanisms behind analytes returning in the bloodstream are welcomed.刊物欢迎阐明血液中分析物再度出现之分子机制的论文。
• The journal seeks clinical interpretations of molecular insights for the implementation of liquid biopsy biomarkers.刊物寻求把分子发现转化为液体活检标志物临床应用场景的解读性研究。
• Technical work on the identification, detection and validation of liquid biopsy biomarkers also falls within scope.关于液体活检标志物识别、检测与验证的技术性工作同样在范围之内。

History

• The International Society of Liquid Biopsy announced the creation of the journal, with Elsevier as publisher, and volume 1 appeared in 2023.国际液体活检学会宣布创办该刊并由（Elsevier）出版，第 1 卷于 2023 年面世。
• It is the official open access scientific journal of the International Society of Liquid Biopsy.刊物是国际液体活检学会的官方开放获取学术期刊。
• The title carries the online ISSN 2950-1954 and is published in New York by Elsevier.刊物使用在线刊号 2950-1954，由（Elsevier）在纽约出版。
• The journal publishes under a fully open access model, with an article publishing charge of about 2,080 US dollars excluding taxes.刊物采用完全开放获取模式，文章处理费不含税约为 2,080 美元。
• It is indexed in PubMed Central, PubMed, Scopus and the Emerging Sources Citation Index.刊物被 PubMed Central、PubMed、Scopus 与新兴来源引文索引收录。
• Its first CiteScore was 3.7, and its 2025 Journal Impact Factor is 5.0.刊物的首个 CiteScore 为 3.7，2025 年期刊影响因子为 5.0。
• Reported publishing times are about three days to first decision and thirty-seven days from submission to acceptance.刊物公布的流程时长约为首次决定 3 天、从投稿到录用 37 天。

Editors

• The Editor-in-Chief is Umberto Malapelle, appointed when the journal was created by the International Society of Liquid Biopsy.主编为（Umberto Malapelle），在刊物由国际液体活检学会创办时受聘。
• Malapelle works on molecular pathology and predictive biomarkers, and leads a multidisciplinary editorial board.（Malapelle）从事分子病理学与预测性生物标志物研究，并领导一个多学科编委会。
• The board is drawn from oncology, pathology, molecular biology and diagnostics, matching the journal's cross-disciplinary reading list.编委会成员来自肿瘤学、病理学、分子生物学与诊断学，与刊物的跨学科定位相称。
• The journal is positioned as a forum for scientific exchange and networking for the liquid biopsy community.刊物被定位为液体活检领域进行学术交流与联络的平台。
• Open access publication means all accepted articles are immediately readable, which the society presents as central to its mission.开放获取出版使所有录用文章立即可读，学会将其视为自身使命的核心。